Semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a lower risk of psychiatric hospitalisation among people with bipolar disorder, according to a study reported by ScienceDaily. Researchers analyzed data from nearly 15,000 individuals with bipolar disorder in Sweden and found that those taking semaglutide had a 21% lower risk of psychiatric hospitalization.
The study suggests the effect may involve biological mechanisms beyond glucose and weight control, including potential changes in inflammation and brain-related pathways that could influence mood stability. ScienceDaily also notes that other drugs in the same broader GLP-1 class were not associated with the same reduction in hospitalisation risk, pointing to a possible drug-specific relationship. The Psychology Headlines source repeats the same findings and interpretation without adding separate reporting details.
While the results are presented as an unexpected mental health benefit, the sources do not describe evidence of symptom improvement or explain whether the association is fully causal, as opposed to reflecting differences in patient characteristics or prescribing patterns.
